[Acute myeloid leukemia]

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Genetic heterogeneity in acute myeloid leukemia (AML) is increasingly understood through novel molecular techniques.
• Genetic diagnostics are crucial for AML classification, prognostication, and guiding genotype-specific therapies.

Purpose of the Study:

• To highlight the importance of rapid pretherapeutic genetic analysis in AML.
• To review current and emerging molecularly targeted therapies for distinct genetic AML subgroups.

Main Methods:

• Screening for recurrent AML-associated gene fusions.
• Mutation analysis of NPM1, FLT3, and CEBPA genes.
• Monitoring minimal residual disease using molecular markers.

Main Results:

• Targeted therapies show promise for specific genetic AML subgroups.
• Combination therapies (e.g., ATRA/ATO, chemotherapy with TKIs) demonstrate improved outcomes.
• Novel approaches targeting epigenetic regulators are under development.

Conclusions:

• Comprehensive genetic characterization is essential for developing targeted AML therapies.
• Individualized treatment strategies based on genetic profiles are improving patient outcomes.